NAV

G207

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
G207
DrugBank Accession Number
DB05827
Background

G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. These viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • G 207
  • G-207
  • Genetically Engineered Herpes Simplex Virus
  • HSV G207
  • HSV-1 G207
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in brain cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

G207, Cancer killing viruses are modified to make them utilizable as a therapeutic agent in human by switching off certain genes that normally enable the virus to multiply in healthy cells, which would destroy these cells. As a result of this genetic modification, the HSVs are able to reproduce in tumor cells solely, since only this offer an environment that compensates for the loss of the removed viral genes. Consequently, the virus is able to replicate in the tumor cells, selectively destroying them without harming healthy tissue.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
WF8NWA83RE
CAS number
Not Available

References

General References
  1. Todo T: Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci. 2008 Jan 1;13:2060-4. [Article]
  2. Radbill AE, Reddy AT, Markert JM, Wyss JM, Pike MM, Akella NS, Bharara N, Gillespie GY: Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. J Neurovirol. 2007 Apr;13(2):118-29. [Article]
PubChem Substance
347910253
Wikipedia
China_National_Highway_207

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Not Yet RecruitingTreatmentAnaplastic Astrocytoma of Brain / Anaplastic Glioma / Giant Cell Glioblastoma / Glioblastoma Multiforme (GBM) / High Grade Glioma (HGG) / Malignant Brain Glioma / Neoplasm1
1Active Not RecruitingTreatmentAstrocytoma / Brain Disorders / Brain Neoplasm / Central Nervous System Disorder / Cerebellar Astrocytoma / Cerebellar Neoplasm Malignant Primary / Cerebellar Neoplasm, Malignant / Cerebellar Neoplasms / Cerebellar Neoplasms, Primary / Diseases of the Nervous System / Glioblastoma Multiforme (GBM) / Glioblastoma of Cerebellum / HSV / Malignant Neoplasm / Malignant Neoplasms of Central Nervous System / Metastatic Cancer / Neoplasm / Neoplasms by Histologic Type / Neoplasms by Site / Neoplasms, Embryonal Germ Cell Tumors / Neoplasms, Glandular and Epithelial / Neoplasms, Nerve Tissue / Neoplasms, Neuroepithelial / Nervous System Neoplasms / Neuroectodermal neoplasm / Pediatric Brain Tumor / Pediatric Primitive Neuroectodermal Tumor of the Cerebellum / Primary Central Nervous System Neoplasms / Primitive Neuroectodermal Tumor / Primitive Neuroectodermal Tumor (PNET) of Cerebellum / Recurrent Medulloblastoma / Viruses1
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Cerebral Primitive Neuroectodermal Tumor / Embryonal Carcinoma / High Grade Glioma: Glioblastoma (GBM) / Malignant Glioma / PNET / Supratentorial Neoplasms, Malignant1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at November 18, 2007 18:28 / Updated at July 18, 2023 22:56